With the rising prevalence of chronic diseases in China, dyslipidemia, hyperglycemia, and hypertension—common metabolic disorders—not only individually threaten public health but also present more complex challenges when occurring as comorbidities, posing significant difficulties for clinical diagnosis, treatment, and public health management. This symposium established a multidisciplinary academic platform, bringing together experts and scholars from clinical medicine, basic research, public health, and health management to delve into the pathogenesis, diagnostic and therapeutic strategies, and holistic management of these "three highs" comorbidities, facilitating the translation of cutting-edge research into clinical practice. With a focus on a population-wide perspective, the symposium aimed to develop personalized and precise prevention and control strategies.

        As the third installment in this series, the event further consolidated the achievements of the previous two conferences by sharing the latest clinical data, treatment guidelines, and management experiences. It fostered collaboration among medical institutions across different regions and levels, providing both theoretical support and practical guidance to enhance China's comprehensive chronic disease prevention and treatment capabilities. Ultimately, the symposium contributed to reducing the burden of comorbidities, improving patients' quality of life, and advancing the Healthy China initiative.